Misato Chimura

Dr. Misato Chimura


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Circulation: Heart Failure
Verified
Journal Article
Open access
MCMisato Chimura
Misato Chimura
MPMark C. Petrie
Mark C. Petrie
MSMorten Schou
Morten Schou
FMFelipe A. Martinez
Felipe A. Martinez
AHAlasdair Henderson
Alasdair Henderson
JMJohn J.V. McMurray
John J.V. McMurray
BACKGROUND: Finerenone improves outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. It is important to understand the efficacy and safety of finerenone in these patients according to age. METHODS: The aim of this analysis was to evaluate the interaction between age and the efficacy and safety of finerenone in the FINEARTS-HF trial (Finerenone Trial to Investigate Efficacy and Safety Compared to Placebo in Patients With Heart Failure). A total of 6001 patients aged 40 to 97 years were stratified by quartile (Q1–Q4) of baseline age: Q1, 40 to 66 years (n=1581); Q2, 67 to 73 years (n=1587); Q3, 74 to 79 years (n=1421); and Q4, ≥80 years (n=1412). FINEARTS-HF evaluated the impact of age on the efficacy of finerenone with respect to the primary composite outcome of cardiovascular death and total (first and recurrent) heart failure events, including heart failure hospitalization or urgent heart failure event, along with secondary efficacy and safety outcomes. RESULTS: The incidence of primary outcomes increased with age. Finerenone reduced the risk of the primary outcome consistently across all age categories: rate ratio in Q1, 0.70 (95% CI, 0.53–0.92); Q2, 0.83 (95% CI, 0.64–1.07); Q3, 0.98 (95% CI, 0.76–1.26); and Q4, 0.85 (95% CI, 0.67–1.07); P interaction =0.27. Similarly, a consistent effect was observed for the components of the primary outcome. The mean increase in Kansas City Cardiomyopathy Questionnaire-total symptom score from baseline to 12 months was greater with finerenone than placebo, with a consistent effect across all age categories: mean placebo-corrected change in Q1, 2.87 (95% CI, 1.09–4.66); Q2, 1.24 (95% CI, −0.59 to 3.07); Q3, 0.94 (−0.98 to 2.86); and Q4, 1.24 (−0.90 to 3.38); P interaction =0.50. Adverse events were similar across all age categories. The odds of experiencing hypotension, elevated creatinine, or hyperkalemia (increased) or hypokalemia (decreased) related to finerenone did not differ by age. CONCLUSIONS: In the FINEARTS-HF trial, finerenone reduced the primary outcome and components of the primary outcome and improved symptoms across a wide age spectrum. In addition, finerenone was safe and well-tolerated, irrespective of age. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT04435626 and EudraCT 2020-000306-29.

12 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMisato Chimura
Misato Chimura
SYShinichiro Yamada
Shinichiro Yamada
YYYoshinori Yasaka
Yoshinori Yasaka
HKHiroya Kawai
Hiroya Kawai
The benefit of revascularization of chronic total occlusion (CTO) in percutaneous coronary intervention (PCI) is controversial. On the other hand, left ventricular (LV) global longitudinal strain (GLS) is a more sensitive marker of LV myocardial ischemia and LV function than LV ejection fraction (EF). The purpose of this study was to investigate the impact of revascularization of CTO on LV function using LV GLS. A total of 70 consecutive patients (65.1±8.9 years, 59 males, LVEF 51.0±12.0%) with CTO who had a positive functional ischemia and underwent PCI, were included in this study. Echocardiography was performed before and 9 months after the procedure with conventional assessment including LV end-diastolic and end-systolic volume (LVEDV, LVESV), LVEF, and with 2DSTE analysis of GLS. Successful PCI was obtained in 60 patients (86%). There were no stent thromboses during follow-up. GLS showed a significant improvement 9 months after successful PCI (pre-PCI -12.4±4.1% vs. post-PCI -14.5±4.1%, P< 0.01), whereas in failed PCI group that did not change significantly (pre-PCI -13.2±4.2% vs. post-PCI -14.0±4.7%, P = 0.64). LVEF, LVEDV and LVESV did not change significantly during follow-up in both successful and failed groups. Successful PCI for CTO improved LV function, assessed by LV GLS.

23 December 2024 in Journal of Asian Pacific Society of Cardiology
Verified
Journal Article
Open access
PDF file
RSRaja Ezman Raja Shariff
Raja Ezman Raja Shariff
HJHaowen Jiang
Haowen Jiang
JYJonathan Yap
Jonathan Yap
STShyn Yi Tan
Shyn Yi Tan
LCLucky Cuenza
Lucky Cuenza
CTCaitlyn Tan
Caitlyn Tan
There remains great heterogeneity in the availability of data and approaches in managing hypertension in Asia-Pacific. A narrative review was performed to better understand the epidemiology of hypertension and challenges in hypertension care provision regionally. The data obtained were discussed under five domains: epidemiology; hospitalisation and financial impact; medication prescription; national guidelines, societies and measures; and barriers and challenges in managing hypertension. Sixteen countries were included, with the prevalence of hypertension ranging between 10.6% and 48.3%. Rates of undiagnosed, untreated and uncontrolled hypertension were alarming throughout the region, with various factors from the five major domains contributing to this, such as urbanisation, gender and socioeconomic status. Data on care provision were generally sparse. Although various measures and policies exist in individual countries to help combat hypertension, challenges have also been identified: some are systemic, while others appear more granular and culturally influenced. Collaboration between stakeholders between countries is crucial to effectively tackle these issues.

24 August 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
MCMisato Chimura
Misato Chimura
SKShinji Koba
Shinji Koba
YSYasushi Sakata
Yasushi Sakata
TITakayuki Ise
Takayuki Ise
HMHiroyuki Miura
Hiroyuki Miura
TTTatsunori Taniguchi
Tatsunori Taniguchi
Introduction Cardiac rehabilitation (CR) is strongly recommended as a medical treatment to improve the prognosis and quality of life of patients with heart failure (HF); however, participation rates in CR are low compared with other evidence-based treatments. One reason for this is the geographical distance between patients’ homes and hospitals. To address this issue, we developed an integrated telerehabilitation platform, RH-01, for home-based CR. We hypothesised that using the RH-01 platform for home-based CR would demonstrate non-inferiority compared with traditional centre-based CR. Methods and analysis The E-REHAB trial aims to evaluate the efficacy and safety of RH-01 for home-based CR compared with traditional centre-based CR for patients with HF. This clinical trial will be conducted under a prospective, randomised, controlled and non-inferiority design with a primary focus on HF patients. Further, to assess the generalisability of the results in HF to other cardiovascular disease (CVD), the study will also include patients with other CVDs. The trial will enrol 108 patients with HF and 20 patients with other CVD. Eligible HF patients will be randomly assigned to either traditional centre-based CR or home-based CR in a 1:1 fashion. Patients with other CVDs will not be randomised, as safety assessment will be the primary focus. The intervention group will receive a 12-week programme conducted two or three times per week consisting of a remotely supervised home-based CR programme using RH-01, while the control group will receive a traditional centre-based CR programme. The primary endpoint of this trial is change in 6 min walk distance. Ethics and dissemination The conduct of the study has been approved by an institutional review board at each participating site, and all patients will provide written informed consent before entry. The report of the study will be disseminated via scientific fora, including peer-reviewed publications and presentations at conferences. Trial registration number jRCT:2052200064.

20 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMisato Chimura
Misato Chimura
SYShinichiro Yamada
Shinichiro Yamada
YTYasuyo Taniguchi
Yasuyo Taniguchi
YYYoshinori Yasaka
Yoshinori Yasaka
HKHiroya Kawai
Hiroya Kawai
Late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is limited in its ability to detect diffuse interstitial fibrosis, which is commonly found in idiopathic dilated cardiomyopathy (DCM). On the other hand, Washout rate (WR) by cardiac 123I- metaiodobenzylguanidine (123I-MIBG) scintigraphy which evaluates cardiac sympathetic nervous function, is a useful tool for predicting the prognosis in DCM. We investigated the predictive value of the combination of two different types of examinations, LGE on CMR and WR by 123I-MIBG scintigraphy for outcomes in DCM compared with LGE alone. One-hundred forty-eight DCM patients underwent CMR and 123I-MIBG scintigraphy. Patients were divided into 4 groups according to the presence or absence of LGE and WR cut-off value of 45% for predicting prognosis based on receiver operating characteristic curve analysis. Cardiac deaths, re-hospitalization for heart failure, implantation of a left ventricular assist device, and life-threatening ventricular arrhythmias were defined as clinical events. Forty-two DCM patients reached the clinical events during the median follow-up for 9.1 years (interquartile range, 8.0–9.2 years).Multivariable Cox regression analysis identified WR≥45%+LGE positive group as an independent predictor of cardiac events (HR 3.18, 95%CI 1.36–7.45, p = 0.008). Notably, there was no significance in the cardiac event-free survival rate between the WR<45%+LGE positive and WR≥45%+LGE negative groups (p = 0.89). The combination of WR by 123I-MIBG scintigraphy and LGE on CMR, which evaluate different type of cardiac deterioration, serves as a stronger predictor of long-term outcomes in DCM patients than LGE alone.

31 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
MCMisato Chimura
Misato Chimura
KDKieran F Docherty
Kieran F Docherty
PJPardeep S Jhund
Pardeep S Jhund
MYMingming Yang
Mingming Yang
RORyohei Ono
Ryohei Ono
JMJohn J V McMurray
John J V McMurray
Background and Aims: The frequency and prognostic significance of abnormalities in serum magnesium concentrations have not been described in a contemporary heart failure (HF) population. The authors evaluated the prognostic significance of magnesium concentrations in patients with HF with reduced ejection fraction (HFrEF) enrolled in GALACTIC-HF trial. Methods: GALACTIC-HF was a randomized, double-blind, multicentre, event-driven trial that investigated the efficacy and safety of omecamtiv mecarbil compared with placebo in HF patients with left ventricular ejection fraction ≤ 35%. The primary outcome was the composite of a first worsening HF event or cardiovascular death. Results: A total of 6147 outpatients had baseline serum magnesium data. Of these, 1082 (17.6%) had magnesium concentrations below .75 mmol/L, 4410 (71.7%) had concentrations within the normal range, and 655 (10.7%) had concentrations above .95 mmol/L. The incidence rate (per 100 person-years) for the primary composite outcome was highest in patients with hypermagnesaemia (34.9, 95% confidence interval 31.2–39.0), while rates were similar between those with hypomagnesaemia (21.5, 19.4–23.8), and normal magnesium (20.9, 19.9–22.0). Similar trends were observed for the components of the primary outcome and all-cause death. The incidence rate of sudden death and ventricular tachyarrhythmia did not differ among the three magnesium groups, but the risk of death from worsening HF was highest in patients with hypermagnesaemia. Conclusions: In GALACTIC-HF, 10.7% of outpatients with HFrEF had hypermagnesaemia, which was associated with a higher risk of the primary outcome compared with normal magnesium concentrations. Abnormal magnesium levels were not associated with a higher risk of sudden death or ventricular tachyarrhythmias. These findings do not support routine correction of hypomagnesaemia.